Value investing message boards image Log on |  Join ($$) Stock market forums image VF "How To" Guide        Welcome, guest! Learn about guest access                       
ValueForum.com Home
• Related Discussion Forum Messages
As a ValueForum member, this section would contain RARE message board posts where the ticker symbol RARE has been mentioned by ValueForum members in posts. Learn more about guest access, and benefits of membership -- we hope you will consider joining ValueForum or trying out our service with a 24 hour trial pass.

• Latest RARE SEC Filings

Filings Format Description Filing Date File/Film Number
8-K  Documents Current report, items 5.02 and 9.01
Acc-no: 0001564590-18-023203 (34 Act)  Size: 1 MB
2018-09-17 001-36276
181073600
CT ORDER  Documents Confidential treatment order
Acc-no: 9999999997-18-007531 (34 Act)  Size: 10 KB
2018-08-30 001-36276
181046760
8-K  Documents Current report, items 8.01 and 9.01
Acc-no: 0001564590-18-022457 (34 Act)  Size: 1 MB
2018-08-29 001-36276
181044439
8-K  Documents Current report, item 5.04
Acc-no: 0001564590-18-022207 (34 Act)  Size: 28 KB
2018-08-22 001-36276
181032951
4  Documents Statement of changes in beneficial ownership of securities
Acc-no: 0001209191-18-047845 Size: 5 KB
2018-08-21
4  Documents Statement of changes in beneficial ownership of securities
Acc-no: 0001209191-18-045878 Size: 4 KB
2018-08-08
8-K  Documents Current report, items 7.01 and 9.01
Acc-no: 0001564590-18-019002 (34 Act)  Size: 80 KB
2018-08-03 001-36276
18990125
10-Q  Documents   Interactive Data Quarterly report [Sections 13 or 15(d)]
Acc-no: 0001564590-18-018979 (34 Act)  Size: 6 MB
2018-08-03 001-36276
18989872
8-K  Documents Current report, items 2.02 and 9.01
Acc-no: 0001564590-18-018901 (34 Act)  Size: 693 KB
2018-08-02 001-36276
18988393
4  Documents Statement of changes in beneficial ownership of securities
Acc-no: 0001209191-18-042706 Size: 4 KB
2018-07-16
More RARE SEC Filings


Related news from
Thu, 20 Sep 2018
19:49:07 +0000
Ultragenyx's Shares Surge More Than 80% in the Year So Far
Ultragenyx's (RARE) share price has increased by about 85.2% year to date based on some positive developments for the product candidates of the company.
Tue, 18 Sep 2018
12:07:48 +0000
See what the IHS Markit Score report has to say about Ultragenyx Pharmaceutical Inc.
Ultragenyx Pharmaceutical Inc NASDAQ/NGS:RARE
Mon, 17 Sep 2018
12:30:00 +0000
Ultragenyx Expands Leadership Team and Appoints Dr. Wladimir Hogenhuis as Chief Operating Officer
Ultragenyx Pharmaceutical Inc. (RARE), a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, today announced that it has expanded its leadership team with the appointment of Wladimir (Vlad) Hogenhuis, M.D., as Chief Operating Officer, effective September 28, 2018. In this newly created role, Dr. Hogenhuis will oversee Global Commercial Operations, Business Development and Technical Operations functions.
Thu, 06 Sep 2018
12:00:00 +0000
Today's Research Reports on Trending Tickers: Agios Pharmaceuticals and Ultragenyx Pharmaceutical
NEW YORK, NY / ACCESSWIRE / September 6, 2018 / Major U.S. equities were mixed on Wednesday with tech stocks posting worst daily drop since July dragging Nasdaq lower. The Dow Jones Industrial Average ...
Thu, 30 Aug 2018
13:50:01 +0000
Ultragenyx to File NDA for LC-FAOD Candidate on Existing Data
Ultragenyx (RARE) plans to submit an NDA for UX007 for the treatment of LC-FAOD on existing data, as per agreement with the FDA.
Wed, 29 Aug 2018
12:30:00 +0000
Ultragenyx Announces FDA Accepts Proposal to Submit an NDA for UX007 for the Treatment of Long-Chain Fatty Acid Oxidation Disorders
Ultragenyx Pharmaceutical Inc. (RARE), a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, today announced that the U.S. Food and Drug Administration (FDA) has accepted Ultragenyx’s most recent proposal to submit a New Drug Application (NDA) for UX007 for the treatment of long-chain fatty acid oxidation disorders (LC-FAOD) based on existing data. “We appreciate FDA’s review of multiple data submissions and collaboration with us to develop a path for an early filing, and it is our commitment to get this important potential treatment to patients with this serious disease as quickly as possible,” said Emil D. Kakkis, M.D., Ph.D., Chief Executive Officer and President of Ultragenyx.
Tue, 28 Aug 2018
21:45:09 +0000
Ultragenyx's Rare Disease Drug Mepsevii Gets EU Approval
Ultragenyx's (RARE) Mepsevii gets European approval for the treatment of Mucopolysaccharidosis VII.
Mon, 27 Aug 2018
20:01:00 +0000
Ultragenyx Announces Approval of Mepsevii™ (vestronidase alfa) in Europe for the Treatment of Mucopolysaccharidosis VII
Mepsevii is now approved for use in all 28 EU countries and in Iceland, Liechtenstein and Norway. “Dr William Sly’s science for this treatment has been around for over 25 years and we are honored to be able to develop and finally make this medicine available to MPS VII patients and families in Europe, people who did not know whether a therapy would ever be available to them,” said Emil D. Kakkis, M.D., Ph.D., Chief Executive Officer and President of Ultragenyx.
Thu, 23 Aug 2018
17:55:22 +0000
Edited Transcript of RARE earnings conference call or presentation 2-Aug-18 9:00pm GMT
Q2 2018 Ultragenyx Pharmaceutical Inc Earnings Call
Fri, 03 Aug 2018
21:38:09 +0000
Ultragenyx (RARE) Posts Narrower-than-Expected Loss in Q2
Ultragenyx posts narrower than expected loss and revenues beat estimates in the second quarter of 2018.
Fri, 03 Aug 2018
00:50:12 +0000
Ultragenyx (RARE) Reports Q2 Loss, Tops Revenue Estimates
Ultragenyx (RARE) delivered earnings and revenue surprises of 10.95% and 180.32%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?
Thu, 02 Aug 2018
23:46:06 +0000
Ultragenyx: 2Q Earnings Snapshot
The Novato, California-based company said it had a loss of $1.06 per share. Losses, adjusted for non-recurring gains, were $1.87 per share. The results topped Wall Street expectations. The average estimate ...
Thu, 02 Aug 2018
20:05:00 +0000
Ultragenyx Reports Second Quarter 2018 Financial Results and Corporate Update
NOVATO, Calif, Aug. 02, 2018-- Ultragenyx Pharmaceutical Inc., a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, today reported its financial results ...
Fri, 27 Jul 2018
12:30:00 +0000
Ultragenyx to Host Conference Call for Second Quarter 2018 Financial Results and Corporate Update
Ultragenyx Pharmaceutical Inc. (RARE), a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, today announced that it will host a conference call on Thursday, August 2, 2018 at 5pm ET to discuss second quarter 2018 financial results and provide a corporate update. Ultragenyx is a biopharmaceutical company committed to bringing to patients novel therapies for the treatment of rare and ultra-rare diseases, with a focus on serious, debilitating genetic diseases. Founded in 2010, the company has rapidly built a diverse portfolio of approved therapies and product candidates aimed at addressing diseases with high unmet medical need and clear biology for treatment, for which there are no approved therapies.



"ValueForum is an active, private, online discussion community for stock & bond market investing. In discussion forums divided into finely grained topics, you will find sophisticated investors trading tips, research, and due diligence on value stocks, income investments, forex, market news, and more. Join in - trade ideas, strategies, current news, via our unique message bulletin boards, stock ratings system, and other online tools specifically geared toward our community."

Random member testimonial: "ValueForum has meant the difference between mediocre and stellar stock performance, peace of mind about retirement and meeting and making wonderful friends. VF is simply the BEST." more testimonials »

Email / About | Privacy | Terms of Use | How To / FAQ | Msg Ticker | VF Home | My.vf | BDCs.vf | Energy.vf | REITs.vf | TA.vf
 
Nothing in ValueForum.com is intended to be investment advice, nor does it represent the opinion of, counsel
from, or recommendations by ValueForum.com. ©2003 - 2018, Powered in part by Ticker TechnologiesContact Us

Stock Market Investing Forum - Trading Tips & Research - Online Message Boards